AU2022900994A0 - Conjugates and their use in therapy - Google Patents

Conjugates and their use in therapy

Info

Publication number
AU2022900994A0
AU2022900994A0 AU2022900994A AU2022900994A AU2022900994A0 AU 2022900994 A0 AU2022900994 A0 AU 2022900994A0 AU 2022900994 A AU2022900994 A AU 2022900994A AU 2022900994 A AU2022900994 A AU 2022900994A AU 2022900994 A0 AU2022900994 A0 AU 2022900994A0
Authority
AU
Australia
Prior art keywords
conjugates
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022900994A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Original Assignee
Centenary Institute of Cancer Medicine and Cell Biology
University of Sydney
Filing date
Publication date
Application filed by Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney filed Critical Centenary Institute of Cancer Medicine and Cell Biology
Publication of AU2022900994A0 publication Critical patent/AU2022900994A0/en
Priority to PCT/AU2022/051236 priority Critical patent/WO2023060317A1/en
Pending legal-status Critical Current

Links

AU2022900994A 2021-10-14 2022-04-13 Conjugates and their use in therapy Pending AU2022900994A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2022/051236 WO2023060317A1 (en) 2021-10-14 2022-10-14 Processes for preparing radiolabelled conjugates

Publications (1)

Publication Number Publication Date
AU2022900994A0 true AU2022900994A0 (en) 2022-04-28

Family

ID=

Similar Documents

Publication Publication Date Title
EP3981434A4 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
ZA200703699B (en) Nitrobenzindoles and their use in cancer therapy
EP4074345A4 (en) Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
EP3762032A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
AU2022299173A1 (en) Novel therapeutic delivery moieties and uses thereof
EP3836950A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP1554306A4 (en) Conjugates comprised of polymer and hiv gp41-derived peptides and their use in therapy
EP3703757A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP4157290A4 (en) Compositions, their uses in therapy and methods thereof
AU2022900994A0 (en) Conjugates and their use in therapy
AU2020903727A0 (en) Conjugates and their use in therapy
EP3995498A4 (en) Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
EP3753579A4 (en) Anti-trailr2 antibody-toxin-conjugate and pharmaceutical use thereof in anti-tumor therapy
IL309249A (en) Conjugates comprising phosphoantigens and their use in therapy
GB202014736D0 (en) Novel compounds and their use in therapy
AU2020901760A0 (en) Nanoparticle conjugates and their use in therapeutic applications
EP3960242A4 (en) Conjugate and cancer therapeutic agent
EP3999092A4 (en) Combination cancer therapy agents and methods
AU2023903793A0 (en) Combination therapy and uses thereof
AU2023902434A0 (en) Combination therapy and uses thereof
GB202305541D0 (en) Novel compounds and their use in therapy
GB202305546D0 (en) Novel compounds and their use in therapy
GB202215142D0 (en) Novel cell lines and their use in therapy
AU2003291896A1 (en) Saponins and sapogenins for use in combination therapy for cancer
GB202110932D0 (en) Novel compounds and their use in therapy